Penumbra, Inc.
NYSE:PENMedical - Devices
-$2.30 today
- Market cap
- $12.64B
- Beta
- 0.70
- P/E (TTM)
- 72.6
- EPS (TTM)
- $4.36
Volume 0.21M
Average 0.50M
PEN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Penumbra, Inc.NYSE: PEN
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $5.62M rose 2.0% year over year, ahead of the -10.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 22.8% from the prior quarter. Over 3 fiscal years it compounded at -10.4% a year.
Context
- Depreciation & amortization amounted to 1.2% of revenue in FY2025, down 0.7 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +2.0% holds above the trailing-twelve-month pace of -10.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 17.47M USD
- Year-over-year change
- -26.3%
- 4-year CAGR
- +1.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.47M | -26.3% |
| FY2024 | 2024-12-31 | 23.7M | -13.0% |
| FY2023 | 2023-12-31 | 27.26M | +12.1% |
| FY2022 | 2022-12-31 | 24.32M | +48.2% |
| FY2021 | 2021-12-31 | 16.41M | — |
Depreciation & Amortization vs competitors
How PEN compares with its peers on the latest reported figures
- PEN's LTM Jun 2026 depreciation & amortization of $17.14M is the 8th largest of the 9 companies compared; the peer median is $515.2M.
- Its year-over-year change of -10.1% is the 8th highest of 9, against a peer median of +6.2%.
- Depreciation & amortization amounts to 1.1% of revenue for PEN, versus a peer median of 7.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $3.33B | +5.9% | -1.6% | 7.1% | |
| LTM Jul 2026 | $2.85B | -3.4% | +3.1% | 7.6% | |
| LTM Jun 2026 | $1.41B | +7.5% | +6.4% | 6.7% | |
| LTM Sep 2026 | $864.9M | +48.9% | +22.8% | 7.5% | |
| LTM Jun 2026 | $165.5M | +9.0% | +3.9% | 2.5% | |
| LTM Sep 2026 | $136.48M | +3.5% | +13.5% | 8.5% | |
| LTM Feb 2026 | $23.19M | -13.4% | -4.2% | 7.4% | |
| LTM Jun 2026 | $17.14M | -10.1% | -10.4% | 1.1% | |
| LTM Mar 2026 | $10.49M | +6.6% | +3.4% | 4.1% | |
| Peer median (excluding PEN) | $515.2M | +6.2% | +3.6% | 7.3% | |
Competitors are the stored peer set for PEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 5.28M | (2M) | 90.95M | 14.01M | 177.69M |
| Depreciation & Amortization | 16.41M | 24.32M | 27.26M | 23.7M | 17.47M |
| Deferred Income Tax | (14.09M) | 1.46M | (19.06M) | (16.34M) | 21.03M |
| Stock-Based Compensation | 0 | 0 | 0 | 46.16M | 59.21M |
| Change in Working Capital | (66.71M) | (121.54M) | (79.08M) | (23.78M) | (42.72M) |
| Accounts Receivables | (21.34M) | (69.86M) | (266K) | 26.6M | (19.51M) |
| Inventory | (51.55M) | (74.63M) | (67.71M) | (65.66M) | (26.48M) |
| Accounts Payables | (1.57M) | 13.39M | 1.1M | 4.17M | 3.07M |
| Other Working Capital | 7.75M | 9.57M | (12.21M) | 11.11M | 213K |
| Other Non-Cash Items | 68.61M | 42.1M | 77.27M | 124.72M | 5.97M |
| Operating Cash Flow | 9.5M | (55.66M) | 97.33M | 168.48M | 238.66M |
| Capital Expenditures | (21.18M) | (19.3M) | (15.21M) | (21.18M) | (63.73M) |
| Acquisitions (Net) | 2.92M | 0 | (988K) | 0 | 0 |
| Purchases of Investments | (126.79M) | 0 | (81.94M) | (32.91M) | (355.74M) |
| Sales of Investments | 123.72M | 74.09M | 82.57M | 130.62M | 14.88M |
| Other Investing Activities | (400K) | 0 | (500K) | 1.1M | 0 |
| Investing Cash Flow | (21.74M) | 54.79M | (16.08M) | 77.62M | (404.59M) |
| Debt Repayment | (1.45M) | (1.75M) | (1.98M) | (2.28M) | (2.49M) |
| Common Stock Issued | 18.37M | 21.55M | 20.41M | 17.17M | 31.82M |
| Common Stock Repurchased | 0 | 0 | 0 | (100.39M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (16.08M) | (8.18M) | (2.23M) | (1.52M) | (2.8M) |
| Financing Cash Flow | 836K | 11.62M | 16.2M | (87.01M) | 26.53M |
| Effect of Forex Changes | 1.11M | (272K) | 168K | (2.18M) | 1.89M |
| Net Change in Cash | (10.29M) | 10.48M | 97.63M | 156.92M | (137.51M) |
| Free Cash Flow | (11.68M) | (74.96M) | 82.12M | 147.3M | 174.93M |
Penumbra, Inc.
NYSE:PEN
Intrinsic Alpha fair value
Locked
Current Price
$320.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.